Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 21605733)

1.

Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial.

McDermott MM, Reed G, Greenland P, Mazor KM, Pagoto S, Ockene JK, Graff R, Merriam PA, Leung K, Manheim L, Kibbe MR, Olendzki B, Pearce WH, Ockene IS.

Am J Med. 2011 Jun;124(6):557-65. doi: 10.1016/j.amjmed.2010.11.032.

2.

Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease.

McDermott MM, Greenland P, Reed G, Mazor KM, Merriam PA, Graff R, Tao H, Pagoto S, Manheim L, Kibbe MR, Ockene IS.

Vasc Med. 2011 Dec;16(6):428-35. doi: 10.1177/1358863X11425879.

PMID:
22128042
3.

Can attention control conditions have detrimental effects on behavioral medicine randomized trials?

Pagoto SL, McDermott MM, Reed G, Greenland P, Mazor KM, Ockene JK, Whited M, Schneider K, Appelhans B, Leung K, Merriam P, Ockene I.

Psychosom Med. 2013 Feb;75(2):137-43. doi: 10.1097/PSY.0b013e3182765dd2. Epub 2012 Nov 28.

4.

A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project.

Keyserling TC, Ammerman AS, Davis CE, Mok MC, Garrett J, Simpson R Jr.

Arch Fam Med. 1997 Mar-Apr;6(2):135-45.

PMID:
9075448
5.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.

PMID:
12479764
6.

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.

Stewart BF, Brown BG, Zhao XQ, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ.

J Am Coll Cardiol. 1994 Mar 15;23(4):899-906.

8.
9.

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M.

J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.

10.
11.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
12.

A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.

Davidson MH, Donovan JM, Misir S, Jones MR.

Am J Cardiovasc Drugs. 2010;10(5):305-14. doi: 10.2165/11584310-000000000-00000.

PMID:
20860413
13.

Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).

Maron DJ, Hartigan PM, Neff DR, Weintraub WS, Boden WE; COURAGE Trial Investigators.

Am J Cardiol. 2013 Jun 1;111(11):1557-62. doi: 10.1016/j.amjcard.2013.02.005. Epub 2013 Mar 25.

PMID:
23538020
14.

Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial.

Pape GA, Hunt JS, Butler KL, Siemienczuk J, LeBlanc BH, Gillanders W, Rozenfeld Y, Bonin K.

Arch Intern Med. 2011 Sep 12;171(16):1480-6. doi: 10.1001/archinternmed.2011.417.

PMID:
21911633
15.

Effects of internet-based tailored advice on the use of cholesterol-lowering interventions: a randomized controlled trial.

Webster R, Li SCh, Sullivan DR, Jayne K, Su SY, Neal B.

J Med Internet Res. 2010 Sep 13;12(3):e42. doi: 10.2196/jmir.1364.

16.

Achieving cholesterol target in a managed care organization (ACTION) trial.

Straka RJ, Taheri R, Cooper SL, Smith JC.

Pharmacotherapy. 2005 Mar;25(3):360-71.

PMID:
15843283
17.

Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial.

Becker DJ, French B, Morris PB, Silvent E, Gordon RY.

Am Heart J. 2013 Jul;166(1):187-96. doi: 10.1016/j.ahj.2013.03.019. Epub 2013 Apr 30.

PMID:
23816039
18.
19.

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.

Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW; Rosuvastatin Investigators Group.

Am Heart J. 2002 Dec;144(6):1044-51.

PMID:
12486429
20.

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).

Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM.

Cardiovasc Diabetol. 2010 May 21;9:20. doi: 10.1186/1475-2840-9-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk